Bharat Biotech has submitted Phase 3 clinical trial data for its Covid-19 vaccine, Covaxin, to the Drug Controller General of India (DCGI). The development comes nearly five months after Covaxin was authorised for emergency usage in the country.

The DCGI’s Subject Expert Committee will take up the matter today. The meeting to review Phase 3 data of Covaxin, the country's first fully homegrown Covid vaccine, will commence at noon.

The Hyderabad-based vaccine maker had stated that its coronavirus vaccine was 81 per cent effective in preventing the infection, according to early analysis of the results from late-stage trials.